News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 06 - 24

Efung News | The First and Only One in China! RuiJing Bio’s NGS-Based Thyroid Cancer Molecular Detec

On June 23, 2026, Shanghai RuiJing Biotechnology Co., Ltd. (hereinafter referred to as "RuiJing Bio") independently developed the "Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit (Joint Probe Anchoring Polymerization Sequencing Method)" officially received a Class III Medical Device Registration Certificate (Registration No.: 20263401321) issued by the National Medical Products Administration (NMPA). As the first and only NGS-based thyroid cancer molecular detection kit approved in China, this certification fills a critical gap in compliant clinical NGS...

浏览次数：15

查看详情>>

发布时间: 2026 - 06 - 22

Efung News | ProteLight Pharma’s World’s First Granulin-Class Antimicrobial Peptide Drug

ProteLight Pharma announced that its independently developed China’s first Class 1 innovative granulin-class antimicrobial peptide drug, Puyike® (Peleganan Spray), received approval for market launch from the National Medical Products Administration (NMPA) on June 17, 2026. The drug is primarily indicated for the treatment of secondary wound infections such as burns and scalds.Peleganan Spray is a First-in-class (FIC) new drug independently developed based on ProteLight Pharma’s Antimicrobial Peptide Drug Design Platform (AMPDDP). The successful approval marks the global debut of the firs...

浏览次数：4

查看详情>>

发布时间: 2026 - 06 - 18

Efung News | Continuously Doubling Down on the World's First Red Blood Cell Innovation Track! Ef

Recently, Westlake Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as "Westlake Therapeutics") announced the completion of a new financing round exceeding RMB 100 million. This round was co-led by Beijing Shijingshan Modern Innovation Industry Development Fund Co., Ltd. ("Shijingshan Modern Innovation Industry Fund") and Ruili Synthetic Biology Fund, with follow-on participation from renowned industrial investors. Existing shareholders including Efung Capital, Huafang Capital, and Sequoia China continued to inject additional capital.The proceeds from this financi...

浏览次数：6

查看详情>>

发布时间: 2026 - 06 - 17

Efung Honor | Efung Capital Named Among 36Kr's 2026 "China Equity Investment Industry Venture Capita

Recently,36Kr's 2026 annual"China Equity Investment Industry Investment Institutions" series rosterwas officially released, with Efung Capital honored as one of the"China Equity Investment Industry Venture Capital Institutions,"and the Waves·2026 "36 Under 36" rosterwas officially announced,with Efung Capital's Zhu Pai named to the list.At the outset of 2026, McKinsey made a judgment in its global private market report: Alpha is no longer found—it is made. Persistently low interest rates, ever-inflating valuation multiples, and readily available cheap...

浏览次数：4

查看详情>>